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Abstract 
Fluid biopsies dependent upon recognition and profiling of circulating tumor cells (CTCs) offer a non-obtrusive 
instrument, encouraging unanticipated disease analysis and treatment monitoring. CTCs attack the remote organs 
by means of the circulatory framework. It has been assessed that primary tumor tosses a million cells day by day 
into dissemination. Notwithstanding, the majority of these cells bite the dust in the circulatory framework and 
just the fittest achieve the ordained area to cause secondary tumors. The identification of CTCs in the blood and 
their characterization can furnish knowledge into the metastatic potential of the primary tumor and the phase of 
the metastasis. This review aims to provide the reader a glimpse of CTCs, their importance in tumor recognition, 
different systems for distinguishing and separation of CTCs from blood, their characterization and the challenges 
ahead to make CTCs a dependable and effective diagnostic device. Such advancement will possibly exchange 
traditional biopsy presenting new period of customised cancer management. 
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1. Introduction 
Tumor is the one of the heading reason for passings on the planet and the toll of human lives is relied upon to 
cross 13 million by 2030 [Ferlay et al., 2008, Globocan]. In its preparatory stage, disease might be 
acknowledged to be a limited illness. However as the stage propels, the sickness spreads to different districts of 
the form by a methodology regarded as metastasis and it is because of metastasis that the majority of deaths 
happen in malignancy. The normal 5- year survival rate for patients with confined and metastatic prostate growth 
is 100% and 28% separately (American Cancer Society, 2013). Grasping and concentrating on the purpose 
behind the metastasis has long been a focal topic in the battle against the debilitating malady. Disregarding the 
enormous expositive expression on metastatic course, there are numerous unknowns all the while (Jemal, Bray et 
al. 2011). 
Carcinogenesis is the methodology of establishment of tumor cells from ordinary cells. If the typical cells are 
triggered by inner components or outside variables to turn into a malignant one, is still a matter of debate. 
Carcinogenesis might be recognized as a Darwinian procedure, comprising of grouping of occasions that could 
be compressed into four fundamental classifications: essential tumor shaping and development, epithelial to 
mesenchymal transition (EMT) and intravasation, haematogenous spread of malignancy and extravasation and 
framing of optional tumor. Haematogenous tissue scattering is the key venture to metastases.  
In the course of the most recent decade, biomarkers have been utilized to recognize and stratify patients who 
might most profit from novel helpful operators. The sign of such exactness therapeutic consideration is the 
distinguishing proof and remedial focusing of BCR-Abl (break point cluster region gene) with imatinib in 
patients with perpetual myelogenous leukaemia (CML). Recent triumphs incorporate focusing on Her2 in breast 
cancer, BRAF gene changes in melanoma3 and EML4 and anaplastic lymphoma kinase (ALK) oncogenic 
combination genes in non-small unit lung carcinoma(King, Casavant et al. 2014). Numerous creators propose 
that an underlying many-sided quality exists in progressive strong tumors and metastatic sores that offer ascent 
to safe clones that escape these therapies. Practicing clinicians are regularly left to depend on tumor aspects (e.g. 
malady stage), basic imaging modalities (e.g. CT or skeletal substance filters), blood biomarkers (e.g. emitted 
proteins, for example, CEA or PSA) that may not correspond with either medication reaction or survival and 
singular patient attributes that anticipate inadmissible poisonous quality from hostile to tumor therapies (i.e. 
patients with poor renal capacity ought not get chemotherapies that are renally discharged). The most clinically 
significant growth biomarkers to date remain tissue biopsies. Biopsy tumor specimens experience morphologic, 
histologic and all the more as of late, genomic aspects to figure out the growth sort and ID of prescient markers 
for medication reaction. Notwithstanding, investigation of documented tumor biopsies regularly don't reflect the 
dynamic adjustments that tumors display at the present time metastases. Later cases studies infer that biopsies for 
thorough examinations can have long-lasting effects on patients. High require in tumor biopsies hinging upon the 
many-sided quality of the infection is further adding to the worries. The contemporary tumor administration 
tools, which essential incorporate radiological imaging and serum tumor markers, are lacking in tending to the 
clinical requirement for compelling clinical disease administration. To enhance the progression free survival 
(PFS) and overall survival (OS) of disease patients, novel and profoundly powerful biomarkers that uncover the 
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molecular cosmetics of the sickness are direly required.  Such biomarkers will enable personalized therapy, 
therapeutic efficacy monitoring, and potentially early diagnosis of cancer. 
The presence of CTCs in cancer patients was first detected in 1869 by an Austrian physician Thomas Ashworth 
who discovered that the blood samples of cancer patients contain small cells which resemble the cells of primary 
tumor (Ashworth, Med. J. Aust. 1869). The belief that CTCs may act as surrogate source of tumor cells triggered 
intensive studies in this field.  The enumeration of CTCs with the survivability of cancer patients confirmed the 
role of CTCs in cancer progression (Fehm, Sagalowsky et al. 2002, Fidler 2003). 
Once the CTCs are shed by the primary tumor, they travel to distant organs of the body not only by the 
lymphatic system by also through blood and form secondary tumors(Chambers, Groom et al. 2002).CTCs have 
been identified in significant numbers in patients with metastases but not in healthy or people with benign 
Tumors.  
But all the CTCs do not have the potential to give rise to secondary tumors (85%) and perish within 2.5 hours. 
Inside the circulatory system, they are subjected to different fates. Studies by Dunn et al. showed that they 
undergo anokis, disintegration by immunoediting or transition to dormant stage while remaining in the 
circulation. They can also undergo cell death following extravasation or they can remain dormant for a long 
period of time (5-25 years) without subsequent aggressive proliferation.  If a CTC successfully evades all the 
above fates in the circulatory system, it can develop a malignant macro metastasis. Although they are extremely 
rare in the circulatory system, their spread is a necessary condition for metastasis (Hanahan and Weinberg 2000, 
Cristofanilli, Budd et al. 2004, Hayes and Paoletti 2013). The diameters of CTCs are 3-4 times as large as the 
pores of the blood capillaries. This means that only a small amount if CTCs remain in circulation, which can be 
detected. Also, these CTCs lodge in the capillaries and undergo apoptosis.  
Recent studies have revealed that CTCs express both stem cell markers and mesenchymal traits, indicating the 
possibility to transitorily acquire stem cell competence following the passage through epithelial to mesenchymal 
transition (EMT). CTCs can be subdivided into three sub-populations: cancer stem cells, tumor amplifying cells 
and tumor initiating cells arising from epithelial cancer cells of the primary tumor which had undergone 
EMT(Yu, Ng et al. 2013). EMT can also induce non-CSCs to enter a CSC like state generating CSCs de-novo. 
The connection between CTCs and CSCs is still unclear(Gupta, Chaffer et al. 2009). Also, CTCs that are not of 
melanoma origin have low expression of epithelial markers.  
The role of circulating tumor micro emboli (CTM) in metastatic development has come up in the recent years. 
CTM consists mainly of tumor cells (at least 2) and blood cells. CTMs have been observed in peripheral blood of 
metastatic lung, liver, colorectal, renal, breast and prostate (Brandt, Junker et al. 1996, Molnar, Ladanyi et al. 
2001, Witzig, Bossy et al. 2002, Vona, Estepa et al. 2004, Paterlini-Brechot and Benali 2007, Hou, Krebs et al. 
2010, Stott, Hsu et al. 2010, Hou, Krebs et al. 2011). The morphology of CTM is highly variable and form as a 
result of the increasing adhesive character of CTCs. Increased study suggests that the presence of CTM could be 
an indication of higher metastatic potential [22,23,25,27]. The conceivable illustration for the expanded 
metastatic potential of CTM, when contrasted with CTCs is because of: i) CTMs are more trapped in the tight 
vasculature than CTCs and ii) CTMs present a favourable microenvironment for tumor cell survival. Likewise, 
extravasation is not an essential for CTM mediated metastasis. 
Comprehending the aspects of CTCs is clinically critical for the advancement of unanticipated tumor 
intercession procedures and medicines.  
 
2. CTC isolation and enrichment 
Over the last decade, a number of strategies to isolate CTCs from billions of RBCs and leukocytes have been 
performed (Figure1). Two factors make the detection and separation of CTCs extremely challenging: i) CTCs 
are extremely are and occur at the rates as low as 1 in 109  erythrocytes and 1 in 107 leukocytes ii) there is no one 
marker to detect CTCs specifically. Leukocytes share many properties with CTCs leading to high level of 
leukocyte contamination in many enriched samples (Yu, Ng et al. 2013).  
Due to the extremely low number of CTCs in blood circulation, an initial enrichment step is done to separate the 
majority of blood cells and from the sample. CTC enrichment is done using various methods like microfluidic 
CTC chips, magnetic particles, microfiltration, dielectric separation and flow cytometry. Once enriched in a 
particular region (most preferably beneath the skin), CTCs are easy to isolate (Figure 2). 
As CTC counts are associated with patient prognosis, a highly sensitive detection strategy is vital to accurately 
identify and enumerate the CTCs isolated. The performance of a typical CTC detection system is evaluated on 
the basis of the parameters as given in the Table1. 
The CTC detection techniques are based on mainly two factors - physical properties (like size, density, electric 
charge and deformability) and biological properties (like protein expression and invasion capacity) (Figure 3). 
2.1 Physical properties based methods 
The difference in biophysical and biomechanical properties of CTC and leukocytes has been used for CTC 
separation since many years (Jin, McFaul et al. 2014). In the early 50s with the wide spread use of Papanicolaou 
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stain, CTCs could be identified with greater certainty. Physical features like lobular, crenelated, elongated nuclei 
and fragmented chromatin became the signs of malignancy. Later studies found that CTCs have many properties 
that could be used for differentiating CTCs form blood cells. Some of these properties include specific gravity, 
size and rigidity. Cluster forming ability of CTC can also be harnessed for label free isolation techniques. 
Automated microscopy and picture investigation of substantial number of fluorescently tagged cells have shown 
the normal diameter of CTCs to associate with 7-9 µm as contrasted with 6-9 µm of leukocytes. Because of 
noteworthy overlapping of sizes, leukocytes may thwart the division routines. Contrasts in nuclear to 
cytoplasmic proportion (N/C ratio) of CTCs and leukocytes exceed by an order of magnitude or more. N/C ratio 
determines deformability of the cells which might be utilized to as an alternate critical property in CTC partition.  
Shape, thickness, electrical polarizability and magnetic susceptibility could be utilized for disengaging CTCs 
from blood. 
Size based isolation has been acknowledged utilizing track carved polycarbonate channels, which are likewise 
utilized in the business ISET and ScreenCell framework for the seclusion of CTCs. The channel is a permeable 
layer holding various haphazardly disseminated 8µm measurement openings that permit blood constituents to 
cross but catch the bigger CTCs (Esmaeilsabzali, Beischlag et al. 2013). Cells frequently remain sound after the 
separation process, allowing their ensuing morphological or molecular investigation. Size based disconnection 
could be performed in the microfluidic setting where the reconciliation of exactly characterized topology of 
microstructures with the laminar stream in the microchannels offer novel answers for cell detachment. Filtration 
is the methodology of streaming a specimen through a show of micro-scale choking influences with a specific 
end goal to catch target cells dependent upon the blending of size and deformability. Filtration microstructures 
could be classified into three essential sorts - weir, column and pore. Weir structures comprise of micro channels 
holding a sudden abatement in the channel cross area. Column structures comprise of an exhibit of micro posts 
dispersed suitably to structure choking influences to catch target units. The pore structure comprise of membrane 
punctured with two dimensional clusters of little gaps. The key outline parameters in these channel 
microstructures incorporate the stream rate of liquid and the cross sectional opening of the constriction. The 
liquid stream rate verifies the force connected to each one cell as it is distorted through the constriction. The 
cross sectional opening figures out the size and state of the cell that might be caught by the channel. Utilizing 
this rule, around 85% of cells could be caught as depicted by Lin and group (Alix-Panabieres and Pantel 2014). 
Be that as it may the key test in utilizing mechanical stipulation to differentiate these cells is the potential of 
clogging when vast amounts of cells are transformed, which can cause eccentric varieties in the stream rate and 
therefore in the force connected to squeeze the units through every narrowing. Other challenge is the extraction 
of cells as they get adsorbed onto the channel material effectively.  Use of crescent shaped traps help to prevent 
clogging by accumulation of cells and other debris. 
Hydrodynamic chromatography utilizes associations between particles and hindrances in stream so as to confer 
diverse stream speeds to distinctive particles dependent upon size contrasts and deformability (Jin, McFaul et al. 
2014). Hydrodynamic chromatography has been utilized within two separate ways. The first works in the low 
Reynolds number administration where inertial impacts might be overlooked while the second one works with 
the Reynolds number of the order of one, where the inertial impacts couldn't be disregarded. Lateral 
displacement of cells could be utilized as a vital property within the low Reynolds number administration. 
Hydrodynamic methodologies can achieve higher throughput than filtration strategies, however the enrichment is 
regularly poorer which is because of its powerlessness to separate nucleated cells, dependent upon deformability. 
Dielectrophoresis (DEP) is fit for segregating between blood cells and tumor cells dependent upon the properties 
of unit size, nuclear and membrane morphology(Jin, McFaul et al. 2014). The point when a cell is suspended in a 
dielectric medium distinct from the cell and is subjected to an electric field, a dipole moment along the course of 
the connected field is created because of charges affected at the interfaces. In the event that electric polarizability 
of the cell surpasses that of the suspending medium, the DEP power will be along the same course as the slope of 
electric field. Hence, cells move towards the solid electric field locale, bringing about positive dielectrophoresis. 
Then again, when the electrical polarizability of the units is less than that of the medium, the cells move towards 
less electric field district. Yield up to 95% could be attained by this procedure. Contrasted with filtration and 
hydrodynamic strategies, dielectrophoresis routines as of now slack in execution in both selectivity and 
throughput. 
Microfluidic devices combining multi-orifice flow fractionation (MOFF) with dielectrophoresis (DEP) and 
dielectrophoretic field flow fractionation (DEP-FFF) are also gaining space in the field due to combinatorial 
approach of different size and membrane properties(Alix-Panabieres and Pantel 2014). 
Cells might be recognized as dielectric particles because of the polarity and the conductivity of the cell 
membrane and cytoplasm (Esmaeilsabzali, Beischlag et al. 2013). The cell when placed in the influence of 
spatially inhomogeneous AC field, taking into account dielectric lands of the cell, the convey medium, the 
recurrence and the adequacy of the field, they will encounter distinctive electrokinetic strengths. These 
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electrokinetic might be utilized for characterization and seclusion CTCs. The only drawback in this process is 
relatively slow processing rate, which limits the rate of sample processing. 
Density gradient centrifugation has also been used to separate CTCs but a significant amount of CTCs were lost 
in this case and hence the method was not encouraged further, though some systems like OncoQuick are based 
on this principle (Arya, Lim et al. 2013, Alix-Panabieres and Pantel 2014).  
Variability in the size of cancer cells of different types and within different cancer cell lines combined with the 
lack of standard definition of performance metrics are the main drawbacks of these physical properties bases 
separation techniques. Training the device to tackle different types of cancer cell line as well as adopting 
standard definition of performance cut-offs can mitigate the problem. 
2.2 Biological properties based methods 
Nucleic acid based methods catch particular DNA or mRNA particles in the example to distinguish the presence 
of CTCs (Phillips, Xu et al. 2009, Xu, Phillips et al. 2009, Cerchia and de Franciscis 2010). These genes code 
for tissue, organ, and tumor particular polypeptides with known mutations found in cancer cells. This 
methodology is most delicate consistent with an exactness of 1 CTC in 5-6 million cells processed. CTC 
recognition utilizing mRNA molecules are by and large more successful. Anyhow nucleic acid based system has 
certain disadvantages- CTCs must be lysed before PCR process which avoids their immediate observation, 
identification and post separation examination. Further, the specificity of the process reduces the overall 
accuracy of the approach as truly CTC specific biomarker is yet to be discovered. So, false positives are also 
detected which include the small number of non-cancer cells that have entered the circulatory system due to 
inflammation, diagnostics biopsies and tumor surgeries. 
As CTCs are shed from solid tumors daily and the majority of them get destroyed, the intracellular components 
like DNA, chromatin, proteins remain in the circulatory system forming circulating tumor materials (CTMat). 
CTMat can also prove to be very useful diagnostic tool as they are present in more number than CTCs (Hong 
and Zu 2013).  
Aptamers (single stranded RNA and DNA) have also demonstrated potential as an alternative identification 
method (Xu, Phillips et al. 2009). The molecular weight of aptamers is around 15 kDa and they are highly 
resistant to adverse conditions like pH, temperature and chemicals. The technique of Systematic Evolution of 
Ligands by Exponential Enrichment (SELEX) has been employed to facilitate the automation of in vitro aptamer 
production. When compared to antibodies, the manufacture of aptamers is much easier and faster. It has been 
suggested that one aptamer binds to one specific antigen on the rare cell. The aptamers can distinguish CTCs 
from normal cells more precisely. An aptamer based, cell affinity chromatography micro device has been 
developed that is capable of isolating tumor cells from a mixture of control cells and sort them. The enrichment 
factor of the micro device is determined to be around 130 times. 
Telomerase are known to be actuated in majority of malignancy of disease sorts and is known to be connected 
with metastatic properties (Hong and Zu 2013). The movement of telomerase have been found in blood samples 
of cancer patients. Since, lifted level of telomerase is one of the signs for stem cell characteristics; this could be 
utilized to distinguish CSCs also. CTCs might be productively identified by telomerase based action however 
entire blood cells must be lysed first which might thwart endeavours to do catch up investigation of CTCs. 
Antigen antibody based bindings are always more efficient and effective approach for detection and isolation of 
CTCs (Alix-Panabieres and Pantel 2014). Antibody based CTC isolation is done using an antibody based matrix 
to which CTCs are specifically bound and either directly or indirectly captured. CellSearch System is the most 
widely used assay to detect CTCs. It is based on an anti-EpCAM immunomagnetic capture step followed by 
fluorescent images that capture nucleated (DAPI +ve), cytokeratin +ve, CD45 –ve events that are designated as 
CTCs. Other CTC detection technologies based on EpCAM include a microfluidic chip (CTC-Chip) which 
contains EpCAM antibodies on the chip platform, HB- Chip (herringbone chip), Ephesia which uses columns of 
bio functionalized super paramagnetic beads assembled on a microfluidic channel onto an array of magnetic 
straps, Magsweeper which can also perform post separation analysis and Velcro like microfluidic device.  
Besides antibody binding, other approaches like E-Selectin and Peptide binding have also been studied. 
Immunomagnetic systems have been used to identify CTCs. CTCs are initially tagged with antibody conjugated 
attractive microbodies or nanoparticles that frequently bind to a particular surface antigen or intracellular 
antigen. The cells when laid open to a non-uniform magnetic field, the labelled cells relocate contrastingly and 
are caught. The execution of an immunomagnetic technique is dependent upon expression and specificity of 
target antigen and binding viability of the antibody, effectiveness of immunolabelling methodology and level of 
detachment in the attractive field. 
Microfluidic bead based nucleic acid sensor can selectively isolate CTC from blood sample (Esmaeilsabzali, 
Beischlag et al. 2013). In this method, micro beads functionalised with HRP and DNA probes act as labels. So, 
two signal amplification approaches are integrated for enhanced detection of CTCs.  
The basic blemishes connected with contemporary biochemical based methodologies is the epithelial to 
mesenchymal transition (EMT) of tumor cells which prompts the loss of epithelial markers on which dominant 
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part of immunological strategies are based. Additionally, the detachment procedure from blood causes perpetual 
connection of the cells to the surface and subsequently restrains their extraction and characterization. 
2.3 Combination Assays 
Combining physical and biochemical properties of tumor cells can increase the efficiency and accuracy of 
detection procedures. A combination of size based hydrodynamic cell sorting and immunomagnetic selection has 
been designed into a device CTC-iChip by Ozkumar et al. successfully.  
Modifying topological properties along with biochemical ones can enhance cell adhesion upto 10 folds as the 
local interactions between nano structured surface and cell membrane are increased(Esmaeilsabzali, Beischlag et 
al. 2013). This forms the basis of adhesion based methods of CTC isolation. Studies have indicated that this 
method captures more invasive subpopulations of CTCs and the cell also remain viable after separation 
procedure. 
Asghar et al., portrayed the creation of strong state micropores in silicon for electrical finger printing, 3D 
profiling and discovery of tumor cells. Under enhanced states of stream rate, they were fit to separate tumor units 
from blood cells, attaining a CTC recognition effectiveness of 70%. 
The Nanovelcro CTC Chip, a unit made out of a designed silicon nanowire substrate (Sinw) and an overlaid 
polydimethylsiloxane (PDMS) confused blender. Accepted by two organizations partaking in the study, the 
Nanovelcro Chip result displays extremely predictable effectiveness in CTC-isolation from patient samples (Lu, 
Zhao et al. 2013). 
Only 50% of patients with metastatic breast cancer have elevated CTC levels and even if the levels are high, 
their relative number in the total blood volume is very less which limits the efficiency of the detection process. 
An assay that increases the sensitivity is more prone to capture non-malignant cells emphasizing the importance 
of second characterization step in the assay. Also, there is a possibility that a captured cell which is 
morphologically and genetically identical to a cancer cell may not have the same metastatic potential. Presence 
of microscopic malignant cells at sites external to the primary tumor is associated with poor prognosis. The 
presences of malignant cells do not imply absolute risk of subsequent recurrence. Meng et al. reported that 36% 
women who had no evidence of clinical disease 7-22 years after mastectomy has detectable aneusonic CTCs. 
Reports by Weidswang indicated that 15% who were diseases free after 3 years of follow up had bone marrow 
micro metastases. After a subsequent follow up period of approximately 3 years, only 21% of these patients with 
documented persistent bone marrow metastases relapsed. Overall, these studies show that high sensitive assays 
may not have clinical implications as predicted. But molecular characterization of CTC will play an important 
role in relation to targeted therapy. 
 
3. CTC characterization 
When CTCs are enhanced and gathered; characterization techniques are required to further research their starting 
point and hereditary profile. Some components must be contemplated while selecting a suitable system for CTC 
identification (Hong and Zu 2013). 
3.1 Immunological detection 
Keeping in mind the end goal to recognize just reasonable CTCs, the practical Epithelial Immunospot 
(EPISPOT) test, joined with any sort of improvement step, was presented for CTC breakdowns. Maintaining a 
strategic distance from immediate contact with the target cells, this strategy surveys the vicinity of CTCs 
dependent upon secreted, shed or discharged proteins. EPISPOT has been connected to blood and skeletal 
substance marrow (BM) samples of bosom, colon and prostate growth patients furnishing first clinical data. 
Furthermore, ultra rapid mechanized computerized microscopy utilizing fiber-optic-array scanning technology 
has been created to catch CTCs that are labelled by antibodies with fluorescent conjugates. Immunological 
detection offers the focal point of consequent seclusion of stained CTCs for ensuing molecular characterization. 
3.2 Molecular detection 
Tests focusing on particular mRNAs are the most broadly utilized alternate choices to immunological examine to 
recognize CTCs. Numerous genes are expressed at low level in normal cells, however, expand their expression 
throughout malignancy. Quantifying their expression level with RT-PCR can set the cut-off for precise 
characterization of samples. The identification of tumor-particular DNA changes is the most particular 
methodology to locate CTCs; notwithstanding, the checked hereditary heterogeneity of robust tumors represents 
an issue on the grounds that distinctive tumors of the same element (e.g., breast carcinomas) and even units 
inside a singular tumor harbour diverse hereditary aberrations. Moreover, hereditary dissection of the essential 
tumor may not foresee the DNA variations on CTCs and seclusion and immediate hereditary examination of 
single CTCs are actually extremely testing. 
3.3 Nanotechnology based detections 
Nano oncology is the most important chapter of nano medicine that has redefined detection and diagnosis of 
cancer(Jain 2010). Gold nanoparticles conjugated with tumor specific antibody target CTC and generate fast 
electrochemical response that is detected with electrochemical methods. Quantum dots conjugated with tumor 
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specific antibodies that bind to tumor specific antigens can also detect CTC specifically that can be detected by 
MRI and fluorescence microscopy. Quantum dots can also bind to methylated DNA which can then be lighted 
up and identified by spectrophotometer. 
3.4 Electrochemical Techniques 
As of late, electrochemical strategies, for example, electrochemical impedance spectroscopy (EIS) and 
voltammetric procedures have picked up premium in the identification and quantification of CTCs in pre 
enriched samples(Jin, McFaul et al. 2014). These methods have been utilized for CTC discovery with up to 
single cell resolution. Numerous studies by research all over the world have produced numerous remarkable 
results; however the most wonderful ones are by Choi et al. who depicted the label free CTC counting utilizing 
DC impedance based microcytometer by exploiting the distinction between the span of CTC and blood cells. For 
estimation they manufactured a microfluidic gadget with two polyelectrolytic gel cathodes and caught change in 
DC impedance relating to the volume of the cell between terminals under low DC voltage. With proposed gadget 
they were able to recognize CTCs in 24 out of 24 BC patient specimens. Subsequently, such an apparatus could 
be utilized for CTC assessment paying little heed to their biomarkers. 
3.5 Photoacoustics based detection 
Photoacoustic imaging has been used for molecular imaging but background signal degrade the detection 
sensitivity and specificity of targets (Nedosekin, Juratli et al. 2013). Most of the noise is due to optical absorbers 
which can be removed if magnetic nanoparticles are used for imaging. Magnetomotive photoacoustic imaging 
helps in the visualization of signal generating objects to great accuracy. Hidden micro metastases can be detected 
using immunomagnetic assays with magnetic nanoparticles that is made up of carbon coated pure iron core 
coated with EpCAM antibodies. Photoacoustic flowmetry, making utilization of the broadband assimilation 
range of melanin, has been tried to identify melanoma cells and has been joined together with nanoparticles 
focusing on unit surface antigens to expand its relevance in CTC detection. Apart from photoacoustics, 
photothermal detection of nanoparticles conjugated to CTCs have been demonstrated successfully. 
3.6 Chemiluminescence  
Chemiluminescence has been used for the identification of CTCs utilizing AuNPs (gold (Yu, Ng et al. 
2013)nanoparticles) as catalysts for the luminol-H2O2 reaction(Zhang, Fu et al. 2013). The high surface-area to-
volume proportion of AuNPs and its catalytic properties towards H2O2 diminishment empowered luminol to be 
oxidized to generate the chemiluminescence indicator, which was identified with a photomultiplier tube (PMT). 
The roles of AuNPs as a versatile CTC catching component, an impetus and sign intensification component for 
chemiluminescence highlight how nanotechnology is influencing CTC detection strategies. 
3.7 Electrical detection 
Electrical discovery is an easy, label free technique which can give constant quantitative recognition of CTCs 
(Yu, Ng et al. 2013). This identification technique could be effortlessly interfaced with size-based affinity, 
ligand-based affinity and DEP-based CTC capture or partition methods. Changes in impedance or conductivity 
as CTCs go between a couple of cathodes could be utilized to identify the vicinity of CTCs. 
3.8 Surface Acoustic Waves 
Surface acoustic wave (SAW) is a delicate, label free technique that might be utilized to catch the coupling of 
CTCs to ligands in real time(Yu, Ng et al. 2013). Interdigitated transducers (IDTs) change over an electrical sign 
into a SAW by utilizing a piezoelectric material and the SAW is transmitted by a managing layer. As the 
coupling occasion changes the mass and thickness at the sensing interface, changes in stage and abundance of 
the SAW happen. The SAW is then changed over once again to an electrical indicator utilizing the IDTs and 
caught. A nanostructured SAW microfluidic chip was utilized for the location of CTCs which generated critical 
effects. 
3.9 µNMR detection 
Micro-atomic attractive thunder (µNMR) is a developing engineering, which is exceedingly well with the 
utilization of magnetic NPs functionalised with legends for CTC catch (Castro, Ghazani et al. 2014). As every 
CTC is bound by numerous ligands functionalised attractive NPs and every NP can likewise tie to some CTCs, 
they structure dissolvable nanoclusters and reason a diminish in the T2 transverse unwinding time of billions of 
nearby water atoms, prompting indicator enhancement and the mass change in T2 transverse unwinding time 
could be recognized, which are characteristic of the articulation levels of the surface antigens on the cells. This 
technique offers high detection sensitivities overcoming technical barriers. 
3.10 Other methods 
A few different systems dependent upon visual microscopy, Atomic force microscopy (AFM), micropipette 
aspiration and optical tweezers are additionally being considered for further enhancement of recognition methods 
of CTCs. Nanostructures substrates have also emerged as a promising platform for better specificity in CTC 
detection. However, non-specific binding and detachment of the cell from the nano-substrate remains an issue. 
Tumor derived microvesicles have been proposed as biomarkers for blood based cancers (Kim, Yong et al. 
2014). Zwitterionic sulfobetaine-conjugated immunobeads are readied utilizing cluster of separation 83 (CD83) 
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as a hopeful protein marker for breast tumor derived microvesicles. The zwitterionic immunobeads are more 
than 10-fold proficient for separating tumor associated microvesicles (TMVs) from clinical plasma samples by 
stifling nonspecific protein tying than ordinary immunobeads. 
One of the major challenges in the therapies against metastases is tumor heterogeneity. Tumor heterogeneity is 
observed between different metastatic sites and the original primary tumor and even within a single tumor at 
metastasis or primary site. Tumor heterogeneity arises mainly from two factors- i) genetic instability which 
causes fixed ‘genetic’ changes in cancer cells and ii) differential but plastic expression of various genes which 
causes resistance to anticancer therapies.  
 
 4. Detecting CTCs in vivo 
CTCs can be targeted directly either by using the Gilupi nanodetector (Alix-Panabieres and Pantel 2014). It also 
based on anti-EpCAM antibodies for detection. The alternative approach is the use of leukapheresis and 
subsequent analysis by flow cytometry and real time PCR for molecular characterisation. 
Most of the modern techniques in CTC diagnosis are either detection or isolation separately. Nano-technology 
combined with X-ray radiation can provide an integrated approach to all the three requirements- enrichment, 
isolation and elimination of CTCs (Hossain, Luo et al. 2012). In this technique, bismuth and magnetic iron oxide 
nanoparticles coated with folic acid are used to target CTC in vivo as CTC over express folic acid receptors on 
their surface. Using micromagnets, CTCs can be enriched to a particular region (beneath the skin) and then 
exposed to X-ray which leads to complete destruction of these cells with minimum toxicity to neighbouring 
normal cells. 
Utilizing hybrid nanoparticles (HNPs) can perform synchronous detection, in situ protein expression analysis, 
and cell phenotype of circulating tumor cells (CTCs) (Lee, Cho et al. 2013). Each HNP comprises of three parts: 
(i) antibodies that bind particularly to a known biomarker for CTC, (ii) a quantum dot that radiates fluorescence 
signs, and (iii) biotinylated DNA that permits isolation and release of CTC-HNP complex based on chip 
technology. 
 
5. Post separation analysis 
The vast majority of the separation strategies lead to the loss of CTCs for further investigation.  Remaining 
suitable disengaged CTCs are utilized for downstream investigation to recognize understanding particular drug 
susceptibilities and configure customized prescriptions. The hereditary dissection and xenograft studies can 
further disentangle the instruments of tumor progression and tumor resistance. Invitro functional assays of CTCs 
have led to the discovery of many markers like MUCIN-1(Hong and Zu 2013). Xenograft studies indicate that 
CTCs have more metastatic potential than parental cell lines indicating their stem cell like properties. Insight into 
cell signalling pathways like Wnt signalling have likewise been found from these studies. The examination of 
CTCs emulating separation step will at last figure out the suitability of an isolation and enrichment methodology.  
 
6. Drawbacks and Challenges ahead 
Circulating tumor cells (CTCs) represent a potential surrogate for tissue-based cancer and hence to monitor serial 
in tumor therapies. Important biomarkers including oestrogen receptor alpha and HER2 have been used for a 
long time in these assays. The failure of cancer therapy is also intrapatient heterogeneity of tumor cells which 
provides a route for resistance. Mathematical modelling shows that genetic instability would result in 
accumulation of mutations and resistance to cancer therapy. Interpretation followed by successful clinical 
application has been proved as a major hindrance in which mathematical modelling can play an important role 
(Hong and Zu 2013). It helps to distinguish rational data from a set of experimental data. Many questions like the 
lowest number of CTC that can be detected in a given sample of blood, how can this number give an estimate of 
total CTC count in the blood and also defines the methodological constraints of cell search system and flow 
cytometry. Skipper et al. also showed that a cytotoxic effect of chemotherapy works best when the tumor 
transplants were recently grafted than the transplants that were allowed to grow for a long time. The expression 
of biomarkers like HER2, ER alpha is different in secondary tumor than from the primary tumor they arose and 
this is the inherent property of the tumor cells. The expression level these biomarkers vary greatly from no 
expression level to high levels of expression. So, the adjuvants that are targeted towards these markers (mTOR, 
ER alpha) and not successful in case of all patients.  
Use of same kinds of chemotherapy for different patients with metastatic disease is widespread which causes the 
tumor to gain resistance for not only one type but all types of chemotherapy. This has led to more and more 
stress on personalized medicine strategy. For eg. persons treated with serial endocrine therapies develop 
resistance towards chemotherapy and vice versa. 
The great hope of CTC research lies in its use to be used as liquid biopsies that would permit more frequent and 
minimally invasive tumor cell tracking unlike the traditional methods. Separation of CTCs from blood has been 
done by various methods based on epithelial antigens; electromagnetic properties of cells and blood flow 
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dynamics, nanotechnology based methods and combined strategies. Use of micro post CTC chip has enabled 
researchers to capture viable CTCs and culture them efficiently. Monitoring the functionality of CTCs has been 
helpful in drug testing, chemotherapy response and metastasis stage diagnosis. Recently, a combination of 
epithelial and mesenchymal cell surface markers has been used to capture all CTCs in blood. The role played by 
platelets in CTC invasion and EMT is coming up now and offers a new dimensions to design strategies based on 
platelets since they are more in number. The integrated approach to enrich, detect and eliminate CTCs within the 
body of the patient can be thought on the basis of chemotactic signalling also. Most the metastatic cancer cells 
are chemotactic to certain factors(Varani 1982). These factors could be specifically injected into a defined region 
of the body followed by a particular incubation time to attract the CTCs. Once the CTCs are detected in 
significant numbers, they could be irradiated from outside or other elimination strategies can be adopted to get 
rid of them. 
To improve the early detection and therapy of cancer cells , better and more efficient ways has to be found for 
the quantitative and qualitative analysis of circulating tumor cells. However, the detection of CTCs is itself a 
challenging task and the lack of reliable markers to detect these cells specifically has hindered the development 
in this field. Till date, no CTC platform is approved to guide clinical care. Still a lot of things need to be done to 
establish the detection and isolation of CTCs to predict the metastases stage in patients. Developing personalized 
medicine based on CTC is also a hope to cancer patients. 
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Figure 1. Schematic Diagram of a Separation System 
 
Figure 2. Overview of CTC management 
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Figure3. Some CTC separation techniques  
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Tables 
Table 1 Evaluation Parameters of a CTC detection system 
Parameter Importance 
Recovery rate 
 
 
Purity Rate 
 
Enrichment rate 
 
 
 
Throughput 
Viability 
It gives the ratio of detected CTCs to total number of CTCs present in the sample. 
This step is crucial to know the stage and early diagnosis of cancer. 
It is equal to the ratio of detected CTCs to all cells in the sample. It defines the 
sensitivity of the system towards CTC isolation. 
It gives an account of the ratio of CTCs to blood cells before and after enrichment. 
It also indicates the sensitivity of the system for CTC isolation and gives an idea 
about the specificity of the marker/property used for the isolation step. 
It indicates the speed by which the sample is processed.  
It indicates the proportion of viable CTCs to all isolated CTCs. 
 
 
Table 2 Various CTC isolation and enrichment technologies 
Method Principle Recovery Purity Throughput Cell 
Viability 
Sensitivity 
ISET 
DEP 
 
 
Inertial force 
 
Cell Search 
 
 
Magsweeper 
 
 
Micropore Chip 
 
CTC iChip 
 
 
 
Nanostructured 
substrates 
Size based 
Dielectric property 
based 
 
Size and weight 
based 
Immunomagnetic 
and fluorescence 
imaging 
Immunomagnetic 
based 
 
Size and elasticity 
 
Combination of 
physical and 
biochemical 
properties 
Bio affinity and 
surface topology 
based 
High 
Variable 
 
 
Low 
 
Medium 
 
 
Medium 
 
 
Medium 
 
Medium- 
High 
 
 
High 
Medium 
Medium 
 
 
Low 
 
Low 
 
 
Medium-
High 
 
Low 
 
Low 
 
 
 
N/A 
 
5 minutes 
30 million 
cells/ 0.5 
hours 
1 million 
cells/ min 
7.5 mL blood/ 
90 minutes 
120 minutes/ 
detection 
round 
0.1 mL 
blood/hour 
10 million 
cells/sec 
 
 
Within 30 
minutes 
High 
Medium 
 
 
High 
 
Not 
viable 
 
High 
 
 
Low 
 
N/A 
 
 
 
High 
 
High 
Medium 
 
 
Medium 
 
High 
 
 
High 
 
 
High 
 
N/A 
 
 
 
High 
 
 
 
 
 
 
Table 3 Post separation analysis 
Methods Inferences 
Size and Morphology 
Deformability assays 
ELISA, PCR, Transcriptome analysis 
DNA sequencing 
FISH and Immunofluorescence 
Functional Assays 
 
Xenograft Studies 
Physical characteristics 
Physical characteristics 
Biomarker characterisation 
Genetic aberration  
Enumeration, detection and identification 
Drug efficiency testing and cell signalling processes 
Biochemical pathways and Stem cell properties 
 
